ARA-290
Cibinetide — 11-amino acid erythropoietin-derived peptide (pyroglutamate helix-B) for innate repair receptor (IRR) signaling, neuropathy, and tissue-protection research
Select size
For research purposes only. Not for human consumption.
Mechanism of Action
ARA-290 (Cibinetide) is an 11-amino acid peptide derived from the helix-B domain of erythropoietin (EPO). Unlike native EPO, it selectively binds the innate repair receptor (IRR) — a heteromer of the EPO receptor and the β-common receptor (CD131) — to activate tissue-protective and anti-inflammatory signaling without engaging the homodimeric EPOR responsible for erythropoiesis.
How It Works
- 1
Binds the innate repair receptor (IRR / EPOR–βcR heteromer) expressed on injured tissues, immune cells, and small-fiber neurons
- 2
Activates JAK2/STAT3, PI3K/Akt, and MAPK pathways to suppress apoptosis and inflammatory cytokine release
- 3
Modulates macrophage polarization toward an M2 reparative phenotype
- 4
Supports small-fiber nerve regeneration in models of diabetic and sarcoid neuropathy
- 5
Does not stimulate erythropoiesis — no effect on hematocrit or red blood cell mass in research models
Key Research Benefits
- Small-fiber neuropathy and nerve regeneration research
- Tissue protection and ischemia/reperfusion injury models
- Anti-inflammatory and macrophage-polarization studies
- Diabetic complication and metabolic neuropathy investigation
- Sarcoidosis-associated chronic pain research
- Non-erythropoietic EPO pathway exploration
ARA-290 (Cibinetide) has been investigated in clinical research for sarcoidosis-related small-fiber neuropathy and diabetic neuropathy, with published studies showing improvements in corneal nerve fiber density and neuropathic pain scores without affecting hemoglobin. Commonly studied alongside BPC-157, TB-500, and Cerebrolysin in neuroregeneration and tissue-repair protocols. Strictly research use only — not for human or veterinary administration.